Phase Ib/IIa trial of TapImmune's TPIV-100 vaccine in patients with HER2/neu-positive breast cancer
Phase of Trial: Phase I/II
Latest Information Update: 05 Apr 2018
At a glance
- Drugs TPIV 100 (Primary)
- Indications Breast cancer
- Focus Therapeutic Use
- 05 Apr 2018 According to a TapImmune media release, this study is fully funded by a grant from the U.S. DoD.
- 15 Nov 2017 According to a TapImmune media release, this trial is expected to begin in 1H 2018.
- 07 Jun 2016 According to a TapImmune media release, the company plans to initiate this trial in 2017.